JP6574257B2 - 新規の抗Ｎｏｄａｌ抗体及びその使用方法 - Google Patents

新規の抗Ｎｏｄａｌ抗体及びその使用方法 Download PDF

Info

Publication number
JP6574257B2
JP6574257B2 JP2017538915A JP2017538915A JP6574257B2 JP 6574257 B2 JP6574257 B2 JP 6574257B2 JP 2017538915 A JP2017538915 A JP 2017538915A JP 2017538915 A JP2017538915 A JP 2017538915A JP 6574257 B2 JP6574257 B2 JP 6574257B2
Authority
JP
Japan
Prior art keywords
nodal
antibody
cancer
seq
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017538915A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017538439A (ja
JP2017538439A5 (enExample
Inventor
メノッティ ルーヴォ，
メノッティ ルーヴォ，
アナマリーア サンドメニコ，
アナマリーア サンドメニコ，
アントニオ レオナルディ，
アントニオ レオナルディ，
ルーカ サンギーニョ，
ルーカ サンギーニョ，
メアリー ジェイ．シー． ヘンドリックス，
メアリー ジェイ．シー． ヘンドリックス，
エリザベス エー． セフター，
エリザベス エー． セフター，
リチャード イー．ビー． セフター，
リチャード イー．ビー． セフター，
ルイージ ストリッツィ，
ルイージ ストリッツィ，
ジーラ ハルハリ−エリス，
ジーラ ハルハリ−エリス，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2017538439A publication Critical patent/JP2017538439A/ja
Publication of JP2017538439A5 publication Critical patent/JP2017538439A5/ja
Application granted granted Critical
Publication of JP6574257B2 publication Critical patent/JP6574257B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
JP2017538915A 2014-10-07 2015-10-07 新規の抗Ｎｏｄａｌ抗体及びその使用方法 Active JP6574257B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462060974P 2014-10-07 2014-10-07
US62/060,974 2014-10-07
PCT/US2015/054515 WO2016057683A2 (en) 2014-10-07 2015-10-07 Novel anti-nodal antibodies and methods of using same

Publications (3)

Publication Number Publication Date
JP2017538439A JP2017538439A (ja) 2017-12-28
JP2017538439A5 JP2017538439A5 (enExample) 2018-11-08
JP6574257B2 true JP6574257B2 (ja) 2019-09-11

Family

ID=55653941

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017538915A Active JP6574257B2 (ja) 2014-10-07 2015-10-07 新規の抗Ｎｏｄａｌ抗体及びその使用方法

Country Status (4)

Country Link
US (3) US9688750B2 (enExample)
EP (1) EP3204414B1 (enExample)
JP (1) JP6574257B2 (enExample)
WO (1) WO2016057683A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE034308T2 (en) 2013-03-21 2018-02-28 Sanofi Aventis Deutschland Preparation of hydantoin-containing peptide products
CN105102427B (zh) 2013-03-21 2018-09-07 赛诺菲-安万特德国有限公司 含有环状酰亚胺的肽产物的合成
US9688750B2 (en) 2014-10-07 2017-06-27 Ann And Robert H. Lurie Children's Hospital Of Chicago Anti-nodal antibodies and methods of using same
WO2018127494A1 (en) * 2017-01-03 2018-07-12 Deinobiotics Methods of producing lipolanthipeptides
US11331019B2 (en) 2017-08-07 2022-05-17 The Research Foundation For The State University Of New York Nanoparticle sensor having a nanofibrous membrane scaffold
EP3801600B1 (en) * 2018-06-05 2025-04-30 University of Mississippi Medical Center PRODUCTION OF ELP MACROPARTICLES AND MICROPARTICLES FOR DRUG DELIVERY
SG11202100721SA (en) 2018-07-23 2021-02-25 Univ Alberta Genetically-encoded bicyclic peptide libraries
WO2020154215A1 (en) * 2019-01-26 2020-07-30 Chien, Du-Shieng Nodal regulation of cancer drug resistance gene
WO2022051495A1 (en) * 2020-09-02 2022-03-10 Ann And Robert H. Lurie Children's Hospital Of Chicago Methods and compositions for the treatment of pulmonary hypertension and cancer
KR102763290B1 (ko) * 2021-09-16 2025-02-05 동아대학교 산학협력단 신규한 샤르코-마리-투스병 제1a형 진단 또는 예후 예측용 바이오마커 및 이의 용도
CN119592689A (zh) * 2024-11-19 2025-03-11 北京肿瘤医院(北京大学肿瘤医院) SMAD2、p38 MAPK作为评估免疫治疗黏膜黑色素瘤效果的标志物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5830663A (en) 1991-08-10 1998-11-03 Medical Research Council In situ recombinant PCR within single cells
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
DE69329974T2 (de) 1992-12-04 2001-07-19 Medical Research Council, London Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US20020086351A1 (en) 1998-08-20 2002-07-04 Reinhard Ebner Human nodal and lefty homologues
US7666423B2 (en) 2006-07-28 2010-02-23 Children's Memorial Hospital Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
JPWO2009051220A1 (ja) * 2007-10-19 2011-03-03 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
US8563279B2 (en) 2007-12-24 2013-10-22 Dsm Ip Assets B.V. Convergent synthesis of renin inhibitors and intermediates useful therein
WO2010042562A2 (en) 2008-10-06 2010-04-15 Minerva Biotechnologies Corporation Muc1* antibodies
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione
US8580714B2 (en) 2009-10-14 2013-11-12 Janssen Biotech, Inc. Methods of affinity maturing antibodies
JP6401060B2 (ja) * 2012-02-24 2018-10-03 アッヴィ・ステムセントルクス・エル・エル・シー 抗ｓｅｚ６抗体及び使用方法
US9688750B2 (en) 2014-10-07 2017-06-27 Ann And Robert H. Lurie Children's Hospital Of Chicago Anti-nodal antibodies and methods of using same

Also Published As

Publication number Publication date
EP3204414C0 (en) 2024-12-04
JP2017538439A (ja) 2017-12-28
US10494428B2 (en) 2019-12-03
EP3204414A4 (en) 2018-03-21
WO2016057683A3 (en) 2016-06-02
US10508147B2 (en) 2019-12-17
US9688750B2 (en) 2017-06-27
US20180319875A1 (en) 2018-11-08
WO2016057683A2 (en) 2016-04-14
US20180298090A1 (en) 2018-10-18
EP3204414B1 (en) 2024-12-04
EP3204414A2 (en) 2017-08-16
US20160130335A1 (en) 2016-05-12

Similar Documents

Publication Publication Date Title
JP6574257B2 (ja) 新規の抗Ｎｏｄａｌ抗体及びその使用方法
JP7270522B2 (ja) 増殖分化因子１５（ｇｄｆ－１５）に対するモノクローナル抗体
KR102584675B1 (ko) GUCY2c에 특이적인 항체 및 이의 용도
CN108602888B (zh) 抑制癌症生长的结合分子
KR102618312B1 (ko) 항muc16 항체 및 그의 용도
JP2023098966A (ja) 成長分化因子１５（ｇｄｆ－１５）に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用
US12441795B2 (en) Anti-ROR1 antibodies and preparation method and uses thereof
KR20200016899A (ko) 활성화가능 항-pdl1 항체, 및 이의 이용 방법
CN105658237B (zh) 抗Ly6E抗体及使用方法
JP2022514693A (ja) Ｍｕｃ１８に特異的な抗体
CN112175085B (zh) 抗gpc3抗体及其用途
JP2022523710A (ja) Ｃｄ４４に特異的な抗体
CN110088137A (zh) 针对mica和micb蛋白的抗体
KR20220110495A (ko) 클라우딘 18.2를 표적화하는 항체-약물 콘쥬게이트
JP2022514786A (ja) Ｍｕｃ１８に特異的な抗体
JP7711208B2 (ja) Ｄｌｌ３に対する結合分子及びその使用
CN113045659B (zh) 抗cd73人源化抗体
KR102887692B1 (ko) 항-bcam 항체 또는 그의 항원 결합 단편
CN116333125A (zh) 结合死亡受体4和死亡受体5的抗体
JP2023511189A (ja) Ｓｅｍｇ２抗体およびその使用
ES2831651T3 (es) Uso de anticuerpos y antagonistas dirigidos contra Lrg1 en un tratamiento
AU2015263827B2 (en) Bak binding proteins
WO2025067400A1 (en) Combination of anti-claudin 18.2/anti-4-1bb antibodies and second therapeutic agent in treatment of cancer
KR20260005325A (ko) 항-ptk7 항체 및 그의 용도
CN120548327A (zh) 抗TGFβ受体1抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180928

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180928

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190717

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190815

R150 Certificate of patent or registration of utility model

Ref document number: 6574257

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250